Aura is a revolutionary rapid
scanning system that will change the
way you look at skin cancer forever.
Read more Intro Video   
vv

The Product // Aura

Introducing Verisante Aura, a revolutionary non-invasive Raman spectroscopy system designed to aid medical professionals in the detection of skin cancer. The system provides valuable information by identifying spectral changes associated with the biochemistry of skin cancer cells in less than a second.

Aura
Verisante Aura was designed to assist medical professionals in the detection of skin cancer by allowing rapid scanning of multiple skin lesions on at-risk individuals. Scans can be accomplished quickly and accurately and can improve patient experience by helping avoid unnecessary biopsies. Not only does Aura have the ability to dramatically speed up the diagnostic process, it has been proven to have a remarkably high sensitivity to detect skin cancer, thereby assisting doctors in detecting skin cancer in its early, most easily treatable stages.

Jointly developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine, this patent protected technology has already been used in a human clinical study spanning six years on approximately 1,000 lesions.
Tested at the renowned Vancouver General Hospital Skin Care Centre, the results published in 2012 showed that Aura can operate at 99% diagnostic sensitivity for differentiating malignant and premalignant skin lesions from benign ones, and reduce the number of unnecessary biopsies by 50%–100%.*

Aura

*Harvey Lui, Jianhua Zhao, David McLean, et al, Real-time Raman Spectroscopy for In Vivo Skin Cancer Diagnosis. Cancer Res 2012;72:2491-2500. Published OnlineFirst March 20, 2012.

The Product // Probe

Probe

A Revolutionary Advancement
in Skin Cancer Detection

Probe Aura provides precision scanning at your fingertips. The compact hand-held probe ensures pinpoint accuracy and is flexible enough to access the most intricate areas of the body; something larger, more cumbersome devices can’t achieve.
And its simple design allows properly trained support staff to quickly and easily scan lesions or moles so the medical professional can make more informed biopsy decisions.



Back to the Top ^

The Technology

Verisante Aura utilizes Raman spectroscopy, a powerful analytical method that uses a laser to probe molecular vibrations and provide very specific, fingerprint-like spectral patterns for identification of the biochemical composition of tissue.

In Raman spectroscopy, near-infrared laser light changes the vibrational state of the bonds within molecules, which in turn causes a shift in the light that is scattered back to a sensor. The magnitude of that shift reveals what molecules are in the sample and at what concentration. The graph shown here is a stylized depiction of the typical spectral differences between malignant melanoma (MM) and a visually similar benign lesion, seborrheic keratosis (SK).
       
MM  SK
Graph


Back to the Top ^

How it Works

Now medical professionals can use rapid
scan technology to aid in the detection of skin
cancer. This simple process provides valuable
information quickly and non-invasively, in less
than a second.

Non-Invasive Precision Scanning
The hand-held probe is held above a mole or lesion. Near-infrared laser light from the probe’s tip is used to illuminate the skin.
Cross-section of the Epidermis
and Malignant Lesion

Light from the probe is scattered identifying biochemical changes associated with a concentration of atypical cells.
Spectral Analysis
Inelastically (Raman) scattered light from targeted skin cells are filtered, dispersed by a grating and detected by a CCD camera for spectral analysis.

Instant Feedback
The Raman spectrum generated by Aura reveals cancer associated biochemical changes in skin tissue immediately.
Saving Time Saves Lives
Using Aura’s proprietary rapid
scan technology to assist in the
detection of skin cancer can
dramatically increase the number
of skin cancer tests you can
perform each week.
Back to the Top ^

FAQs

1

I am a highly trained and skilled Dermatologist, why do I need a machine to do what I already do extremely well?

A number of studies have shown that the accuracy of clinical diagnosis of melanoma by dermatologists varies between 49% and 81%, with approximately one third of melanomas being misdiagnosed as benign lesions. A clinical study demonstrated that Aura appears to be favorable in comparison with clinicians as well as other technical diagnostic aids. Aura is a noninvasive technique, which provides a rapid and accurate second opinion within seconds. (Cancer Research, Vol. 72, p.2491)
2

What assurances can I have that this machine is better than the other systems we have seen?

Aura is much faster and has higher sensitivity and specificity performance than any other device with automatic score algorithms on the market as well as those still under development that we know of. Aura results are displayed to the dermatologist within a second. Confocal microscopy has competitive performance but does not have automatic algorithms thus the interpretation of the results has to be made by expert assessment of the acquired images. Confocal imaging devices also take several minutes to scan a single lesion. Aura is the only device that has been developed by a government cancer agency and leading university dermatology department. It is the only device that detects all major skin cancers.
3

Why might a pathology report come back negative even though an AuraScan said it had a high similarity to a malignant lesion?

The device does produce some false positives, especially at very high sensitivity levels. Keep in mind that pathologists are looking at cellular morphology and Aura is measuring molecules. Pathologists can disagree with clinicians and other pathologists, too.
4

I have or still offer mole mapping, why should or how should I incorporate this?

Aura works well in combination with serial monitoring devices that use total body photography and dermoscopic imaging. In the mole mapping software the operator would click on the suspicious lesion in question and then a comments box will open where the AuraScan result can be entered. The Aurascan result, in combination with the dermoscopic images, can be used to monitor suspicious lesions, maintain records, and make biopsy decisions. This combination would be highly recommended for patients who have a history of melanoma.
5

What is Raman Spectroscopy?

Raman spectroscopy is a noninvasive optical technique capable of measuring vibrational modes of biomolecules within viable tissues. The Raman spectrum is also regarded as the fingerprints of the molecules.
6

Why do we need to use a new AuraTip for each new patient?

The calibration tip ensures that the device is still properly calibrated for each measurement and also to prevent cross contamination between patients.
7

What areas can I not diagnose with Aura (contraindications)?

Nails, eye lids, mucosal tissue (on lips and genitals) because these areas have not been a part of the clinical study. They may be added to Aura’s lable in the future based on post market approval studies.
8

Why isn’t this procedure covered under our general exam or consult fee?

We are not aware of any reimbursable fee codes for Raman spectroscopy for skin cancer detection.

Back to the Top ^

How to Buy

The most revolutionary advancement in skin cancer detection is now available for sale.

Aura
Aura is currently available for sale in Canada, Europe and Australia. To purchase or learn more about how Aura can benefit your practice, please contact us directly.
In Germany, please contact:

LaserWelt
Uhlandstrasse 175
Ecke Kurfürstendamm
D-10719 Berlin
Tel 49 (0) 30 887744 110
info@laserwelt.com
www.laserwelt.com

In Belgium, the Netherlands,
Luxembourg, Denmark, Sweden,
Norway, Iceland and Finland
please contact:


bo medical technologies
Cannenburgerweg 11b
1244 RE, Ankeveen
Tel 035 6550101
henk-peter.oonk@bo-medical.com
www.bo-medical.com

In Switzerland, please contact:

Pacifca Handels AG
Sophi Comte
Director of Sales
Tel 41 79 617 10 93
hscomte@pacifica-ag.ch
www.bo-medical.com

In the UK, please contact:

Frontiere Medical Europe, LLC
6 rue de Chaillot
Paris, 75116 France
Tel 44 (0) 7562 600 555
daniel@frontmed.org
www.frontmed.org

In Western Canada, please contact:

Kim Ellis
Sales Representative
Verisante Technology, Inc.
kellis@verisante.com


For all other regions, please contact:

Jason Mangler
Verisante Technology, Inc.
Director of Sales
jmangler@verisante.com
Verisante
Verisante is a medical device company committed to the development and commercialization of innovative systems for the early detection of skin cancer. The company’s proprietary platform technology is also fully expandable to early detection systems for other types of cancers.

Back to the Top ^